Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria

This is not the most recent version

view the current version 19 August 2020

Information

DOI:
https://doi.org/10.1002/14651858.CD012656Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 04 May 2017see what's new
Type:
  1. Intervention
Stage:
  1. Protocol
Cochrane Editorial Group:

  1. Cochrane Infectious Diseases Group

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Rachael Milligan

    Correspondence to: Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK

    [email protected]

  • André Daher

    Research and Reference Laboratories, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil

  • Patricia M Graves

    College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia

Contributions of authors

Patricia Graves (PMG), Paul Garner (CIDG Co‐ordinating Editor) and Rachael Milligan (RM) contributed to the conception of the research question.
All protocol authors contributed to the protocol design and approved the final version.

Sources of support

Internal sources

  • Liverpool School of Tropical Medicine, UK.

External sources

  • Department for International Development, UK.

    Grant number: 5242

Declarations of interest

RM has no known conflicts of interest.
AD has no known conflicts of interest.
PMG has no known conflicts of interest.

Acknowledgements

We are grateful to Vittoria Lutje, the Information Specialist of the Cochrane Infectious Diseases Group (CIDG) for help with the literature search strategy. We thank Marty Richardson, CIDG statistician, for help with the data collection and analysis strategy. Rachael Milligan is supported by the Effective Health Care Research Consortium. This Consortium and the CIDG editorial base are funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this Cochrane protocol do not necessarily reflect UK government policy.

Version history

Published

Title

Stage

Authors

Version

2020 Aug 19

Primaquine alternative dosing schedules for preventing malaria relapse in people with <i>Plasmodium vivax</i>

Review

Rachael Milligan, André Daher, Gemma Villanueva, Hanna Bergman, Patricia M Graves

https://doi.org/10.1002/14651858.CD012656.pub3

2019 Jul 05

Primaquine at alternative dosing schedules for preventing relapse in people with <i>Plasmodium vivax</i> malaria

Review

Rachael Milligan, André Daher, Patricia M Graves

https://doi.org/10.1002/14651858.CD012656.pub2

2017 May 04

Primaquine at alternative dosing schedules for preventing relapse in people with <i>Plasmodium vivax</i> malaria

Protocol

Rachael Milligan, André Daher, Patricia M Graves

https://doi.org/10.1002/14651858.CD012656

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Adult; Child; Humans;

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection
Figures and Tables -
Figure 1

Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection

Navigate to figure in ProtocolOpen in new tab
Table 1. Data extraction: Grouping of comparisons to address the review objectives

Objective

Intervention

Control

Are higher doses more effective (0.5 mg/kg or 30 mg primaquine/day for 14 days), in all areas, or only in areas where they are standard treatment (Asia, Pacific)?

Blood‐stage antimalarial drug with primaquine 0.5 mg/kg (30 mg) per day for 14 days (total dose 420 mg)

Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection.

Blood‐stage antimalarial drug with primaquine 0.25 mg/kg (15 mg) per day for 14 days (total dose 210 mg)

Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection.

Are shorter, higher dose regimes of primaquine over 7 days as effective as treatment over 14 days (is the total dose rather than the length of treatment the important factor)?

Blood‐stage antimalarial drug with primaquine 0.5 mg/kg (30 mg) per day for 7 days (total dose 210 mg)

Both intervention and control groups must have received the same treatment: either CQ or ACT for the blood‐borne stage of infection.

Are weekly dosing regimens (0.75 mg/kg or 45 mg/week for 8 weeks) as effective?

Blood‐stage antimalarial drug with primaquine 0.75/kg (45 mg) per week for 8 weeks (total dose 360 mg)

CQ = Chloroquine

ACT = Artemisinin‐based combination therapy
Figures and Tables -
Table 1. Data extraction: Grouping of comparisons to address the review objectives
Navigate to table in Protocol